Impact of inflammatory bowel disease and azathioprine on long-term outcomes after liver transplantation for primary sclerosing cholangitis.

Abstract

We read with interest the multicentre retrospective study by Irlès-Depé et al1 reporting the impact of inflammatory bowel disease (IBD) on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC). In their series PSC-IBD patients were found to have similar rates of death, recurrent PSC (rPSC) and malignancy as patients with isolated PSC. Moreover azathioprine (AZA) exposure was associated with increased mortality, an association which may have been due to an era effect.